2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
生物活性
Description
In Vivo
In Vitro
化合物的使用
Kinase Assay
Cell Assay
Animal Administration
参考文献
Description of AZD2461: AZD2461 is a novel and potent PARP inhibitor with lower affinity to P-glycoprotein. AZD2641 is currently in Phase I clinical study. The study is being conducted to see how it may work to treat solid tumors. The main purpose is to establish a safe dosage of the drug and provide additional information on any potential side effects this drug may cause. The study will also assess the blood levels and action of AZD2461 in the body over a period of time and will indicate whether the drug has a therapeutic effect on solid tumors.
For the detailed information about the solubility of AZD2461 in water, the solubility of AZD2461 in DMSO, the solubility of AZD2461 in PBS buffer, the animal experiment（test） of AZD2461,the in vivo,in vitro and clinical trial test of AZD2461,the cell experiment（test） of AZD2461,the IC50, EC50 and Affinity of AZD2461, please contact DC Chemicals.
